ACIP Recommendations for Pneumococcal Vaccination

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVP,Mary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

The panel of experts examines the most recent ACIP recommendations for pneumococcal vaccination in adults aged 65 and older, highlighting key updates and changes to the guidelines.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

Now Viewing

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

EP: 11.Insights on Conjugate Pneumococcal Vaccines

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

What do the updated ACIP recommendations suggest for pneumococcal vaccination in adults aged 65 and older? High-risk adults aged 19-64?

Patients can receive PCV20 if they have already received PCV13 (at any age) and PPSV23 (at or after the age of 65 years old). What is the significance of receiving PCV20 after receiving PCV13 AND PPSV23?